Hengrui Pharmaceuticals-Backed Nanjing Tianyinshan Hospital Opens as Class 3A Oncology Specialist Center
Nanjing Tianyinshan Hospital, a private Class 3A oncology specialist hospital invested in by Hengrui Pharmaceuticals...
Jiangxi Jemincare Group Secures Clinical Trial Approvals for Six Drugs in China and the US
China-based Jiangxi Jemincare Group (SHA: 603222) has announced receiving clinical trial approvals for six of...
Baidu Health and Chongqing’s Fifth People’s Hospital Collaborate on Integrated Medical Services
Baidu Health has entered into a partnership with the Fifth People’s Hospital of Chongqing, a...
Suzhou Ribo Life Science Strikes Deal with Qilu Pharmaceutical for PCSK9 siRNA Drug
Suzhou Ribo Life Science Co., Ltd, a specialist in small interfering RNA (siRNA) drugs based...
CStone Pharmaceuticals Regains Exclusive Rights to Tibsovo in Greater China and Singapore
CStone Pharmaceuticals (HKG: 2616), a China-based biopharmaceutical company, has announced an agreement with French pharmaceutical...
Yifan Pharmaceutical’s F-652 Shows Promise in Phase II Clinical Trial for ACLF
Yifan Pharmaceutical Co., Ltd (SHE: 002019), a China-based pharmaceutical company, has reported positive outcomes from...
Takeda Ends Gene Therapy Collaboration with JCR Pharmaceuticals, Returns IP
Takeda Pharmaceuticals Company Limited (TYO: 4502) has announced the termination of a 2022 collaboration agreement...
Sanofi Halts Development of Tusamitamab Ravtansine After Missed Trial Endpoints
Sanofi (NASDAQ: SNY) has announced the discontinuation of its antibody-drug conjugate (ADC) tusamitamab ravtansine following...
CNIPA Releases Updated Patent Law Rules with Pharma Industry in Focus
The China National Intellectual Property Administration (CNIPA) has announced the “Decisions of the State Council...
China’s CDE Issues Draft Guidelines for Overseas Drug Market Approval Filings
China’s Center for Drug Evaluation (CDE) has unveiled a draft set of “Application Material Requirements”...
BMS to Acquire Karuna Therapeutics for $14 Billion, Expanding Psychosis Treatment Portfolio
Bristol Myers Squibb (BMS; NYSE: BMY), a leading US pharmaceutical company, has announced its intention...
CStone Pharmaceuticals Disbands Sales Team for Gavreto After NRDL Setback
CStone Pharmaceuticals (HKG: 2616) has confirmed media reports regarding the dismissal of its sales team...
Roche Diagnostics and Beijing Strong Biotechnologies Deepen Ties to Innovate in Hemostasis Diagnostics
Roche Diagnostics (SWX: ROG), the Swiss diagnostics heavyweight, has furthered its collaboration with Beijing Strong...
Asieris Pharmaceuticals Gets Australian Greenlight for Acinetobacter Infection Drug Trial
Asieris Pharmaceuticals (SHA: 688176), a China-based specialist in urogenital cancer treatments, has received approval in...
Kossel Medtech Secures Over $14 Million in Series B Financing to Boost International Expansion
Kossel Medtech (Suzhou) Co., Ltd., a company specializing in coronary and peripheral intervention medical devices,...
Sino Biopharmaceutical Completes Enrollment for Phase III Trial of Anlotinib in Soft Tissue Sarcoma
Sino Biopharmaceutical Ltd (HKG: 1177), a China-based pharmaceutical giant, has announced the completion of patient...
Jiangsu Nhwa Pharmaceutical Gets NMPA Green Light for Schizophrenia Drug Trial
Jiangsu Nhwa Pharmaceutical Co., Ltd. (SHE: 002262), a China-based pharmaceutical company, has announced that it...
Legend Biotech’s Carvykti Therapy to Include Myeloid Neoplasms Warning in Label Update
GenScript Biotech Corporation (HKG: 1548), a China-based Contract Research Organization (CRO), has announced that its...
Takeda’s Livtencity Receives NMPA Approval, a First in China for CMV Infection Treatment
Japanese pharmaceutical company Takeda (TYO: 4502) has received its first market approval from China’s National...
China Grand Pharmaceutical to Acquire Majority Stake in Mitsubishi Tanabe’s Tianjin Subsidiary
China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced its intention to...